GlobeNewsWire - Nicox SA (COX) Nicox Provides Fourth Quarter 2023 Financial and Business Highlights

Almost there...

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

First Name*

Last Name*

Country*

Email*

Password* ( 6 or more alphabetic and numerical characters )

Get financial insights straight to your inbox

YES

I have read and accept ResearchPool Terms & Conditions, and Privacy Policy, including our Cookie Use Policy

Already on ResearchPool? Login Now

COX Nicox SA

Nicox Provides Fourth Quarter 2023 Financial and Business Highlights

Press Release
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
NCX 470 Phase 3 Denali clinical trial 75% randomized Net revenue €1.3 million for fourth quarter 2023 and €4.2 million for the full year 2023, an increase of 29% compared to the full year 2022 Cash of €11.9 million on December 31, 2023 The Company is financed to June 2024, bas

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

COX Nicox SA

Nicox Provides Fourth Quarter 2023 Financial and Business Highlights

Nicox Provides Fourth Quarter 2023 Financial and Business Highlights